PRPH חוב כולל להון ProPhase Labs

ProPhase Labs, Inc. (PRPH) is a leading player in the genomic testing and contract research segment, ensuring a stable cash flow through deep automation. Back-office efficiency is increasing via the implementation of accounting software platforms and AI modules. The price action for the total debt-to-equity ratio is 1.19, which is critical amid severe pricing pressure from major networks during the post-pandemic demand slump.

This ratio is calculated as total liabilities divided by total equity, determining the business's degree of dependence on debt financing. By analyzing the debt-to-equity ratio, an investor assesses the financial stability of ProPhase Labs, Inc. (PRPH), which is critical when scaling centralized laboratories to reduce unit costs for diagnostic tests.